APA

Garciaz S., Loschi M., De Masson A., Biard L., Mercier M., Tomowiak C., Delage J., Labussiere-Wallet H., Sibon D., Cassuto O., Borel C., Cornillon J., Nimubona S., Charbonnier A., Brice P., Socié G., Bouabdallah R., de Latour R. P. & de Fontbrune F. S. (20200828). Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. : Leukemia & lymphoma.

Chicago

Garciaz Sylvain, Loschi Mickael, De Masson Adèle, Biard Lucie, Mercier Mélanie, Tomowiak Cécile, Delage Jeremy, Labussiere-Wallet Hélène, Sibon David, Cassuto Ophélie, Borel Cécile, Cornillon Jérome, Nimubona Stanislas, Charbonnier Amandine, Brice Pauline, Socié Gérard, Bouabdallah Reda, de Latour Régis Peffault and de Fontbrune Flore Sicre. 20200828. Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. : Leukemia & lymphoma.

Harvard

Garciaz S., Loschi M., De Masson A., Biard L., Mercier M., Tomowiak C., Delage J., Labussiere-Wallet H., Sibon D., Cassuto O., Borel C., Cornillon J., Nimubona S., Charbonnier A., Brice P., Socié G., Bouabdallah R., de Latour R. P. and de Fontbrune F. S. (20200828). Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. : Leukemia & lymphoma.

MLA

Garciaz Sylvain, Loschi Mickael, De Masson Adèle, Biard Lucie, Mercier Mélanie, Tomowiak Cécile, Delage Jeremy, Labussiere-Wallet Hélène, Sibon David, Cassuto Ophélie, Borel Cécile, Cornillon Jérome, Nimubona Stanislas, Charbonnier Amandine, Brice Pauline, Socié Gérard, Bouabdallah Reda, de Latour Régis Peffault and de Fontbrune Flore Sicre. Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. : Leukemia & lymphoma. 20200828.